2017版和2009版国家医保药品目录对比研究

Research on the Contrast about National Reimbursement Drug List between 2009 and 2017

目的:探索《国家基本医疗保险、工伤保险和生育保险药品目录(2017年版)》(以下简称《2017版药品目录》)的调整方向,为指导各省制定省级增补目录提供依据。方法:运用EXCEL和SPSS 18.0对《国家基本医疗保险、工伤保险和生育保险药品目录(2009年版)》和《2017版药品目录》进行对比分析,比较二者差异。结果:《2017版药品目录》中药品种数增加明显,新增了谈判药品目录;《2017版药品目录》西药的分类方式发生改变;目录增补品种多,剔除药品少;医保目录新增剂型多为颗粒剂、口服液体制剂;甲乙类药品增长比例基本一致;国家增强了药品适应症支付限制,减少了对医保门诊的报销限定。结论:本次医保目录调整重点扶持中药和民族药,关注高值药品和儿童药,药品分类更为细化,目录管理日趋严格。

Objective： To explore the adjustment direction of new National Reimbursement Drug List 2017（NDRL） and provide guidance ＂about supplement of Reimbursement Drug List for each province. Methods： Comparing the differences about NDRL between 2009 and 2017 by EXCEL and SPSS 18.0. Results： More drugs and negotiated drugs were added into the new NDRL. The classifica- tion method of western drugs had been changed. The amount of supplementary drugs was more than eliminated drugs. The main dos- age of supplementary drugs form were granules and oral liquid. The growth proportion of Class-A and Class-B were similar. The gov- ernment had imposed restrictions on drug indication and canceled limit to reimbursement of outpatient service. Conclusion： The new NDRL supported with the hand the traditional Chinese medicine and pays more attention to expensive drugs and pediatric drugs. It al- so subdivided the drug classification and make catalog management more strictly.